Overview

A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU

Status:
Active, not recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This study is a phase II single-arm study designed to evaluate the efficacy and safety of P1101 in Chinese PV patients who are intolerance or resistance to HU.
Phase:
Phase 2
Details
Lead Sponsor:
PharmaEssentia